{"public_id":"cl_4748f9cc02e9886235d5096f69a0750d","status":"active","superseded_by_public_id":null,"corpus_id":11837230,"text":"DYRK1A inhibitors have emerged as promising therapeutics for reducing cognitive deficits in Down syndrome.","confidence":0.97,"paper":{"corpus_id":11837230,"title":"DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome","url":"https://sah.borca.ai/papers/11837230"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.97,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_7e7bc3e24f1026003552009d2a582289","name":"DYRK1A inhibitors","description":"Small-molecule or related compounds designed to inhibit DYRK1A activity.","types":["therapeutic agent","drug development target"],"url":"https://sah.borca.ai/concepts/co_7e7bc3e24f1026003552009d2a582289"},{"public_id":"co_933ef62d2ae0eabeeeb93f14df4ab451","name":"cognitive deficits","description":"Impairments in learning and memory discussed as a major outcome in Down syndrome.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_933ef62d2ae0eabeeeb93f14df4ab451"},{"public_id":"co_994773436ae804456edbc1688b94afd3","name":"Down syndrome","description":"A chromosomal disorder associated with intellectual disability and multiple health complications.","types":["condition"],"url":"https://sah.borca.ai/concepts/co_994773436ae804456edbc1688b94afd3"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_4748f9cc02e9886235d5096f69a0750d"}